<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:06:09Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5604297" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:5604297</identifier><datestamp>2017-09-21</datestamp><setSpec>bmcmd</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Med. Genet</journal-id>
      <journal-title-group>
        <journal-title>BMC Medical Genetics</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2350</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5604297</article-id>
      <article-id pub-id-type="pmcid">PMC5604297</article-id>
      <article-id pub-id-type="pmc-uid">5604297</article-id>
      <article-id pub-id-type="pmid">28923014</article-id>
      <article-id pub-id-type="publisher-id">460</article-id>
      <article-id pub-id-type="doi">10.1186/s12881-017-0460-1</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title><italic>SCN8A</italic> mutations in Chinese patients with early onset epileptic encephalopathy and benign infantile seizures</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Wang</surname>
            <given-names>Jiaping</given-names>
          </name>
          <address>
            <email>wangjiaping321@126.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Gao</surname>
            <given-names>Hua</given-names>
          </name>
          <address>
            <email>gaoh@mail.cbi.pku.edu.cn</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3670-159X</contrib-id>
          <name>
            <surname>Bao</surname>
            <given-names>Xinhua</given-names>
          </name>
          <address>
            <email>zwhang@pku.edu.cn</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Qingping</given-names>
          </name>
          <address>
            <email>zhangqp1988@126.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Jiarui</given-names>
          </name>
          <address>
            <email>lijr@mail.cbi.pku.edu.cn</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Wei</surname>
            <given-names>Liping</given-names>
          </name>
          <address>
            <email>weilp@mail.cbi.pku.edu.cn</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>Xiru</given-names>
          </name>
          <address>
            <email>wxrwwn@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>Yan</given-names>
          </name>
          <address>
            <email>cydoc1991@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yu</surname>
            <given-names>Shujie</given-names>
          </name>
          <address>
            <email>yushujie2008520@163.com</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1764 1621</institution-id><institution-id institution-id-type="GRID">grid.411472.5</institution-id><institution>Department of Pediatrics, </institution><institution>Peking University First Hospital, </institution></institution-wrap>Beijing, 100034 China </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2256 9319</institution-id><institution-id institution-id-type="GRID">grid.11135.37</institution-id><institution>Center for Bioinformatics, State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, </institution><institution>Peking University, </institution></institution-wrap>Beijing, China </aff>
        <aff id="Aff3"><label>3</label>Department of Neurology, Harbin Childrenâs Hospital, Harbin, Heilongjiang Province 150010 China </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>18</day>
        <month>9</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>18</day>
        <month>9</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2017</year>
      </pub-date>
      <volume>18</volume>
      <elocation-id>104</elocation-id>
      <history>
        <date date-type="received">
          <day>1</day>
          <month>6</month>
          <year>2017</year>
        </date>
        <date date-type="accepted">
          <day>8</day>
          <month>9</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Â© The Author(s). 2017</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p id="Par1">
<italic>SCN8A</italic> mutations have recently been associated with epilepsy and neurodevelopmental disorders. This study aimed to broaden the phenotypic-spectrum of disease related with <italic>SCN8A</italic> mutations.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p id="Par2">To identify the pathogenic gene of a Chinese family, in which six members suffered from epilepsy, whole-exome sequencing was performed. In addition, target next-generation sequencing (NGS) was performed on 178 sporadic patients, who had epilepsy of unknown etiology within 6Â months after birth. A detailed clinical history was obtained.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p id="Par3">A heterozygous missense mutation of <italic>SCN8A</italic> was identified in the Chinese family. Six de novo mutations of <italic>SCN8A</italic> were detected in 6 sporadic patients with epilepsy. In the family, six members developed seizures within a few years after birth. Five of them had milder clinical performance, that they had normal cognition and developmental milestones, and seizure-free was achieved by mono-therapy. The other one affected member presented with refractory epilepsy and developmental regression. She died from sudden unexpected death in epilepsy (SUDEP) at 17-year-old. Clinical features of six sporadic patients with <italic>SCN8A</italic> mutations were diverse, ranging from severe epileptic encephalopathy to benign epilepsy with normal cognition. Seizures started at the mean age of 3.9Â months (from 2Â months to 6Â months). Seizure-free was achieved in four of them by mono- or multi-antiepileptic drugs. Five of them demonstrated mild or severe psychomotor retardation, whereas the other one was normal in development and intelligence.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p id="Par4">Our findings extend the spectrum of <italic>SCN8A</italic> mutations and the clinical features of patients with <italic>SCN8A</italic> mutations. The majority of <italic>SCN8A</italic> mutations were de novo, inherited mutations from the heterozygous parents can also occur. The phenotypic spectrum of <italic>SCN8A</italic> mutation varied largely. Most affected patients manifested as refractory epilepsy and severe intellectual disability, only a small number of patients presented with milder clinical patterns. Additionally, our study confirmed that the same mutation can lead to different phenotypes.</p>
        </sec>
        <sec>
          <title>Electronic supplementary material</title>
          <p>The online version of this article (10.1186/s12881-017-0460-1) contains supplementary material, which is available to authorized users.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>
          <italic>SCN8A</italic>
        </kwd>
        <kwd>Epileptic encephalopathy</kwd>
        <kwd>Family cases</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution>Peking University and Clinical Hospital Cooperation Project </institution>
          </funding-source>
          <award-id>2013-1-06</award-id>
          <principal-award-recipient>
            <name>
              <surname>Bao</surname>
              <given-names>Xinhua</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
        <award-group>
          <funding-source>
            <institution>Technology innovation talents special fund of Harbin Science and Technology Bureau</institution>
          </funding-source>
          <award-id>2016RAXYJ089</award-id>
          <principal-award-recipient>
            <name>
              <surname>Yu</surname>
              <given-names>Shujie</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>Â© The Author(s) 2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p id="Par22">Voltage-gated sodium channels (VGSCs) play a critical role in controlling neuronal excitability. VGSCs contain one pore-forming Î±-subunit and one or two Î² subunits. The Î±-subunit is made up of four repeated homologous domains (IÂ ~Â IV), each domain containing a motif of six transmembrane segments (S1Â ~Â S6) and an additional pore loop located between the S5 and S6 segments [<xref ref-type="bibr" rid="CR1">1</xref>]. So far, 9 VGSCs Î±-subunits (Na<sub>v</sub>1.1Â ~Â Na<sub>v</sub>1.9) have been identified. Among these 9 Î±-subunits, Na<sub>v</sub>1.1, 1.2, 1.3 and 1.6, which are encoded by <italic>SCN1A</italic>, <italic>SCN2A</italic>, <italic>SCN3A</italic> and <italic>SCN8A</italic> respectively, are primarily expressed in the central nervous system. Mutations in these genes can result in epilepsy [<xref ref-type="bibr" rid="CR2">2</xref>â<xref ref-type="bibr" rid="CR5">5</xref>].</p>
      <p id="Par23">The Na<sub>v</sub>1.6 Î±-subunit is encoded by <italic>SCN8A</italic>, which is highly expressed along the axonal initial segment (AIS) and the nodes of Ranvier of myelinated axons [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Na<sub>v</sub>1.6 is directly involved in action potential generation and conduction. Mutations of <italic>SCN8A</italic> are associated with type 13 of early infantile epileptic encephalopathy (EIEE 13) (OMIM #614558) [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. The phenotypic spectrum of diseases caused by <italic>SCN8A</italic> mutations varied largely. Most patients had intractable epilepsy beginning at the first year of life, accompanied by severe developmental delay and intellectual disability. <italic>SCN8A</italic> mutations can also lead to milder phenotype, such as benign infantile seizures (BFIS)/infantile convulsion and paroxysmal choreoathetosis (ICCA) [<xref ref-type="bibr" rid="CR10">10</xref>]. Part of patients with <italic>SCN8A</italic> mutations presented only mental retardation without epilepsy [<xref ref-type="bibr" rid="CR11">11</xref>]. In this study, seven <italic>SCN8A</italic> mutations were identified in a Chinese family and six sporadic patients with unknown etiological epilepsy, including four previously described mutations and three <italic>novel</italic> mutations.</p>
    </sec>
    <sec id="Sec2">
      <title>Methods</title>
      <sec id="Sec3">
        <title>Patients and samples</title>
        <p id="Par24">A Chinese family was recruited in this study, in which six members spanning 3 generations were affected with epilepsy (Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>). All of them were female, and aged from 2 to 61Â years old. <italic>PCDH19</italic> gene mutation was ruled out in this family. The proband had focal seizures at the age of 6Â months. Seizure frequency ranged from one time per month to 6 times per day. She was treated with valproic acid (VPA) at 8Â months of age. Seizure-free was achieved at 1Â year old. III-5 had similar clinical course as the proband. Seizures attacked at 6-month-old, which was also controlled by VPA.II-2 and I-2 suffered from febrile convulsions during childhood, which evolved into afebrile seizures after 10Â years old for both of them. Seizure-free was achieved in both of them, by treatment with Phenytoin (PHT) and Carbamazepine (CBZ) respectively. II-4 had focal seizures during the preschool period, and there were no seizures reported since six years old, even without treatment. Another member (II-3) in this family had been suffering from epilepsy since she was less than one-year-old. Unfortunately, seizures were not controlled by CBZ. Early development was normal for her. However, after seizures onset, she had significant retrogression in cognition, and gradually lost the ability of walking and speaking. At 17Â years old, she died from sudden unexplained death in epilepsy (SUDEP). Except II-3, other five affected members in the family had normal cognition and motor function, and neurological examinations were unremarkable. Detailed clinical information of the affected individuals in this family was summarized in TableÂ <xref rid="Tab1" ref-type="table">1</xref> and AdditionalÂ fileÂ <xref rid="MOESM1" ref-type="media">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>The pedigree of family case with <italic>SCN8A</italic> mutation.I-2, II-2, II-4, III-2, III-4, were analyzed by whole-exome sequencing. III-5 was tested by Sanger sequencing</p></caption><graphic xlink:href="12881_2017_460_Fig1_HTML" id="MO1"/></fig>
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Clinical features of affected member of <italic>SCN8A</italic> mutation in the pedigree</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Patient</th><th>Gender</th><th>Age (death)</th><th>Age of onset</th><th>Seizure type</th><th>Motor development</th><th>Cognitive outcome</th><th>EEG (age)</th><th>Respond to AEDs</th></tr></thead><tbody><tr><td>I-2</td><td>F</td><td>61y</td><td>&lt;5 y</td><td>Febrile convulsion evolved into afebrile seizure during school-age</td><td>Normal</td><td>Normal</td><td>â</td><td>Seizures free from 11 y with PHT</td></tr><tr><td>II-2</td><td>F</td><td>35y</td><td>3 y</td><td>Febrile convulsion evolved into afebrile seizure after 10 y</td><td>Normal</td><td>Normal</td><td>â</td><td>Controlled by CBZ, no seizures for more than 5 y to date</td></tr><tr><td>II-3</td><td>F</td><td>(17y)</td><td>&lt;1 y</td><td>Focal seizure</td><td>regressed</td><td>regressed</td><td>â</td><td>Not controlled by CBZ</td></tr><tr><td>II-4</td><td>F</td><td>27 y</td><td>Preschool period</td><td>Focal seizure</td><td>Normal</td><td>Normal</td><td>â</td><td>Untreated, seizures resolved</td></tr><tr><td>III-4</td><td>F</td><td>6y, 9 mo</td><td>6Â m</td><td>Focal seizure</td><td>Normal</td><td>Normal</td><td>Normal (6Â m)</td><td>Seizures free from 1-year-old with VPA</td></tr><tr><td>III-5</td><td>F</td><td>2 y, 9 mo</td><td>6Â m</td><td>Focal seizure</td><td>Normal</td><td>Normal</td><td>
<bold>â</bold>
</td><td>No seizures after 1Â years old with VPA</td></tr></tbody></table><table-wrap-foot><p>
<italic>m</italic> months, <italic>y</italic> years, <italic>F</italic> female, <italic>PHT</italic> phenytoin, <italic>VPA</italic> valproic acid, <italic>CBZ</italic> carbamazepine</p></table-wrap-foot></table-wrap>
</p>
        <p id="Par25">In addition, a total of 178 sporadic patients having unknown etiological epilepsy were recruited. All of the patients had epilepsy, and met one or more of the following criteria: 1) seizures onset within 6Â months, especially within 3Â months after birth; 2) intractable epilepsy with frequent seizures; 3) severe electroencephalography (EEG) abnormalities, including hypsarrhythmia, burst-supperession, etc.; 4) severe psychomotor retardation, with or without regression. We excluded the patients with neonatal or infant epileptic seizures caused by metabolic diseases, brain injury during perinatal period, central nervous system infection or other known etiologies.</p>
        <p id="Par26">The detailed clinical information was collected by periodic follow-up, including medical history, family history, curative effects by antiepileptic drugs (AEDs), MRI, EEG, etc.,. Genomic DNA was extracted from peripheral leukocytes. Written informed consent was obtained from the subjects. This study was approved by the Peking University First Hospital Medical Ethics Committee.</p>
      </sec>
      <sec id="Sec4">
        <title>Whole-exome sequencing</title>
        <p id="Par27">Whole-exome sequencing was used to detect the mutated gene in the family. Probes were designed to cover the whole-exome. Sequencing was performed on Ion torrent Proton high-throughput platform (Themofisher) using a paired-end sequencing of 200Â bp to screen the mutations. Fast QC v0.10.1 was used to filter out reads of low base quality score. BWA software was used to align the reads to the hg19 genome. Unified Genotyper and HapolotypeCaller in Genome Analysis Tool KIT v3.2 (GATKv3.2) were used to call variants.</p>
      </sec>
      <sec id="Sec5">
        <title>Targeted NGS</title>
        <p id="Par28">Targeted NGS was used to screen gene mutations in 178 sporadic patients with epilepsy of unknown cause. A custom-designed panel capturing the coding exons of 485 genes (AdditionalÂ fileÂ <xref rid="MOESM2" ref-type="media">2</xref>) related to epilepsy and intellectual disability, including <italic>SCN8A</italic>, was synthesized using NimbleGenSeqCap Target Enrichment technique. NGS was subsequently performed on Ion torrent Proton high-throughput platform (Themofisher).</p>
      </sec>
      <sec id="Sec6">
        <title>Mutations annotation</title>
        <p id="Par29">All the mutations were confirmed by Sanger sequencing. Rare mutations, whose population frequency was less than 1%, were filtered according to the 1000Â Genomes data, ESP6500 population data and ExAC data. Reported pathogenic mutations in HGMD Professional database and Pubmed were marked. The pathogenicity of other rare mutations was annotated by Mutation Taster and PolyPhen-2.</p>
        <p id="Par30">Sanger sequencing was performed to analyze the parental origin of those variants. Then the causative mutations were confirmed according to parental origin of the variants and the clinical features of the patients.</p>
      </sec>
    </sec>
    <sec id="Sec7">
      <title>Results</title>
      <sec id="Sec8">
        <title>Molecular analysis</title>
        <p id="Par31">Five members, including four patients (I-2, II-2, II-4, III-4) and one phenotypic normal member (III-2) in the Chinese family were analyzed by whole-exome sequencing (Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>). Meanwhile, patient III-5 was not born yet. A total of 23 candidate gene mutations were identified (AdditionalÂ fileÂ <xref rid="MOESM3" ref-type="media">3</xref>). After III-5 was born and presented with seizures at age of 6Â months, Sanger sequencing of these 23 candidate genes was performed on the newborn. Then it was narrowed to 10 candidate genes including <italic>SCN8A</italic> and 9 other genes (TableÂ <xref rid="Tab2" ref-type="table">2</xref>)<italic>.</italic> Among these candidate genes, 7 genes were neither expressed in nervous system, nor reported to be associated with epilepsy or other neurologic disorders. <italic>ANGPT4</italic> has been related to Alzheimerâs disease and vascular dementia. <italic>IMPA1</italic> has been associated with bipolar disorder previously. But the variants of them detected in this family were also frequent in ExAC and 1000Â Genomes database. <italic>SCN8A</italic> has been related with EIEE 13, benign infantile epilepsy, and cerebellar ataxia. It is widely expressed in central nervous system and had been reported in patients with epilepsy. The heterozygous missense mutation (c.4793Â TÂ &gt;Â C, p.Val1598Ala) of <italic>SCN8A</italic> identified in this family was not mentioned in any known database (dbSNP138, 1000G, EVS, ExAC). The mutation site was highly conserved from insects to mammals (Fig.Â <xref rid="Fig2" ref-type="fig">2h</xref>), and was predicted as damaging by Mutation Taster and PolyPhen-2 (TableÂ <xref rid="Tab3" ref-type="table">3</xref>). So <italic>SCN8A</italic> was considered to be the causative gene of the family.<table-wrap id="Tab2"><label>Table 2</label><caption><p>10 candidate genes identified in the family case and their related disease</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Gene</th><th>Related disease</th><th>Inheritance</th><th>Transcript</th><th>Mutation</th><th>Allele carriers in ExAC</th><th>Allele carriers in 1000Â G</th></tr></thead><tbody><tr><td>
<italic>SCN8A</italic>
</td><td>Cognitive impairment with or without cerebellar ataxia; EIEE13; Seizures, benign familial infantile, type 5</td><td>AD</td><td>NM_014191.3</td><td>c.4793Â TÂ &gt;Â C, p.Val1598Ala</td><td>0</td><td>0</td></tr><tr><td>
<italic>ANGPT4</italic>
</td><td>Alzheimerâs disease, vascular dementia</td><td>Unknown</td><td>NM_015985</td><td>c.68AÂ &gt;Â T, p.Gln23Leu</td><td>3</td><td>83</td></tr><tr><td>
<italic>IMPA1</italic>
</td><td>Mental retardation, type 59</td><td>AR</td><td>NM_001144878</td><td>c.856AÂ &gt;Â G, p.Ile286Val</td><td>2</td><td>â</td></tr><tr><td>
<italic>POP1</italic>
</td><td>Anauxetic dysplasia, type 2</td><td>AR</td><td>NM_001145860</td><td>c.2861GÂ &gt;Â A, p.Arg954His</td><td>1</td><td>â</td></tr><tr><td>
<italic>RYR3</italic>
</td><td>Atherosclerosis; HIV Infections</td><td>Unknown</td><td>NM_001243996</td><td>c.12448GÂ &gt;Â A, p.Asp4150Asn</td><td>23</td><td>2</td></tr><tr><td>
<italic>SLC16A3</italic>
</td><td>Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, type 2</td><td>Unknown</td><td>NM_004207</td><td>c.44CÂ &gt;Â T, p.Ala15Val</td><td>600</td><td>57</td></tr><tr><td>
<italic>TDRD7</italic>
</td><td>Cataract, autosomal recessive, type 36</td><td>AR</td><td>NM_014290</td><td>c.474GÂ &gt;Â A, p.Met158Ile</td><td>14</td><td>1</td></tr><tr><td>
<italic>PKP2</italic>
</td><td>Arrhythmogenic right ventricular cardiomyopathy, type 9</td><td>AD</td><td>NM_001005242</td><td>c.2200AÂ &gt;Â G, p.Ile734Val</td><td>6</td><td>1</td></tr><tr><td>
<italic>LAMA3</italic>
</td><td>Epidermolysis bullosa, generalized atrophic benign; Epidermolysis bullosa, junction, Herlitz type; Laryngoonychocutaneous syndrome</td><td>AR</td><td>NM_198129</td><td>c.7462GÂ &gt;Â A, p.Asp2488Asn</td><td>â</td><td>â</td></tr><tr><td>
<italic>C6ORF165</italic>
</td><td>No related diseases reported</td><td>_</td><td>NM_001031743</td><td>c.274AÂ &gt;Â G, p.Trp92Ala</td><td>96</td><td>7</td></tr></tbody></table><table-wrap-foot><p>
<italic>AD</italic> autosomal dominant, <italic>AR</italic> autosomal recessive, <italic>EIEE 13</italic> Epileptic encephalopathy, early infantile, type 13</p></table-wrap-foot></table-wrap>
<fig id="Fig2"><label>Fig. 2</label><caption><p>Seven <italic>SCN8A</italic> mutations identified in this study <bold>a</bold>-<bold>g</bold> and conservation of the altered amino acid of three unreported mutations shown in the ClustalW alignments <bold>h</bold>
</p></caption><graphic xlink:href="12881_2017_460_Fig2_HTML" id="MO2"/></fig>
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Seven <italic>SCN8A</italic> (NM_014191.3) mutations identified in our study</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Patient</th><th>Mutation</th><th>Chromosome 12: position</th><th>Domain</th><th>Mutation taster</th><th>PolyPhen-2</th><th>Reported/Novel</th></tr></thead><tbody><tr><td>Patient 1</td><td>c. 694Â TÂ &gt;Â C, p.Ser232Pro</td><td>52,082,621</td><td>DIS4</td><td>Disease causing</td><td>Probably damaging</td><td>
<italic>Novel</italic>
</td></tr><tr><td>Patient 2</td><td>c.2549GÂ &gt;Â A, p.Arg850Glu</td><td>52,159,459</td><td>DIIS4</td><td>Disease causing</td><td>Probably damaging</td><td>Reported [<xref ref-type="bibr" rid="CR14">14</xref>]</td></tr><tr><td>Patient 3</td><td>c. 5614CÂ &gt;Â T, p.Arg1872Trp</td><td>52,200,884</td><td>C-terminal</td><td>Disease causing</td><td>Probably damaging</td><td>Reported [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]</td></tr><tr><td>Pateint 4</td><td>c. 423GÂ &gt;Â A, p.Gly1475Arg</td><td>52,184,185</td><td>DIIIS6-DIVS1 loop</td><td>Disease causing</td><td>Probably damaging</td><td>Reported [<xref ref-type="bibr" rid="CR15">15</xref>]</td></tr><tr><td>Patient 5</td><td>c.5630AÂ &gt;Â G, p.Asn1877Ser</td><td>52,200,900</td><td>C-terminal</td><td>Disease causing</td><td>Possibly damaging</td><td>Reported [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]</td></tr><tr><td>Patient 6</td><td>p.2671GÂ &gt;Â A, p.Val891Met</td><td>52,159,581</td><td>DIIS5</td><td>Disease causing</td><td>Probably damaging</td><td>
<italic>Novel</italic>
</td></tr><tr><td>Pedigree</td><td>c.4793Â TÂ &gt;Â C, p.Val1598Ala</td><td>52,188,423</td><td>DIVS3</td><td>Disease causing</td><td>Probably damaging</td><td>
<italic>Novel</italic>
</td></tr></tbody></table><table-wrap-foot><p>The positions of the mutations on chromosome 12 refer to the reference sequence that was retrieved from the NCBI database (build 37)</p></table-wrap-foot></table-wrap>
</p>
        <p id="Par32">By targeted NGS, heterozygous mutations in seven genes (<italic>CDKL5, KCNQ2, KCNT1, STXBP1, SCN2A, SCN8A, SLC2A1</italic>) were detected in 59 patients. The gene mutation rate was 33% (59/178). <italic>SCN8A</italic> gene mutations were identified in six patients (Fig.Â <xref rid="Fig2" ref-type="fig">2a-f</xref>). All six mutations were de novo, which were predicted highly damaging the function of Na<sub>v</sub>1.6 channel by Mutation Taster and PolyPhen-2 (Table <xref rid="Tab2" ref-type="table">2</xref>). Four of them have been confirmed pathogenic previously (TableÂ <xref rid="Tab3" ref-type="table">3</xref>). The other two <italic>novel SCN8A</italic> mutations (c.694Â TÂ &gt;Â C, p.Ser232Pro and c.2671GÂ &gt;Â A, p.Val891Met) are located at the extremely conserved positions (Fig.Â <xref rid="Fig2" ref-type="fig">2h</xref>). A schematic representation of the Na<sub>v</sub>1.6 channel, including the locations of mutations identified in this study, is shown in Fig.Â <xref rid="Fig3" ref-type="fig">3</xref>.<fig id="Fig3"><label>Fig. 3</label><caption><p>The structure of the human Nav1.6 channel and the location of <italic>SCN8A</italic> mutations identified in this study. Red Dots: Novel; black dots: reported</p></caption><graphic xlink:href="12881_2017_460_Fig3_HTML" id="MO3"/></fig>
</p>
      </sec>
      <sec id="Sec9">
        <title>Clinical and neurophysiological findings</title>
        <sec id="Sec10">
          <title>Family case</title>
          <p id="Par33">The clinical information of six affected patients was summarized in Table <xref rid="Tab1" ref-type="table">1</xref>.</p>
        </sec>
        <sec id="Sec11">
          <title>Sporadic cases</title>
          <p id="Par34">Six patients were identified having <italic>SCN8A</italic> mutations, including four males and two females. The clinical features of them were diverse, of whom four presented severe epileptic encephalopathy, whereas the other two had much milder clinical course. The age of epilepsy onset ranged from 2Â month to 5Â month, averaging at 3.9Â months. Focal seizure was the most common semiology, observed in all six of them. Seizure-free was achieved in four of them eventually.</p>
          <p id="Par35">Patient 1 had focal seizures beginning at two months after birth. Seizures attacked 2â3 times every day. He was treated with Topiramate (TPM) at 3Â months of age, and achieved a seizure-free period as long as 45Â days. At 5Â months old, seizures recurred, and the frequency was 10 times per day. Levetiracetam (LEV) was used but without remission. Then VPA was added, and seizure frequency was reduced to 5â6 times per day. TPM was stopped at 8Â months old, and Clonazepam (CZP), Oxcarbazepine (OXC) was added at 11Â months of age. By treatment with multi-drugs (VPA, OXC, CZP), no seizures were observed since from one year of age. He presented with severe developmental delay and is currently (32Â months of age) unable to sit independently.</p>
          <p id="Par36">Patient 2 was discovered to have epilepsy at 3Â months of age. The initial seizure type was focal seizure. Seizures attacked 7â8 times per day. He was treated with LEV at 5Â months, but no good outcome was reported. At 9Â months of age, myoclonic seizures were observed. EEG at that time showed generalized high amplitude multi-spike and slow waves. At age of 1Â year and 7Â months, LEV was substituted by VPA, and seizure frequency was reduced to 3 times per day. By 1Â year and 11Â months, Lamotrigine (LTG) was added for treatment, and no seizures were reported after 2Â years old. The developmental milestones were far behind his peers, that he could not control his head until 28Â months old.</p>
          <p id="Par37">Patient 3 began to have seizures at age of 3.5Â months, including focal seizures, secondary generalized seizures, and status epilepticus. It was as frequent as 10â15 times per day. EEG at 1-year-old showed slow background and spikes at right central area during sleep. He remained have seizures at age of one year, even with multi-therapy (LEV, TPM, VPA and OXC). Developmental delays caused concern since from 3Â months of age, when poor head control was observed, and there was no apparent improvement throughout the follow-up period (one-year-old). As patient 3 was loss to follow-up, his current status was not clear.</p>
          <p id="Par38">Patient 4 developed epilepsy at 4Â months old. The initial seizure type was focal seizures. Generalized seizures were also observed. Seizures attacked 1â2 times per week. She was treated with VPA at 5Â months of age, but showed no signs of remission. Then TPM was added at 6Â months old. By treatment with VPA and TPM, she had no seizures for 6Â months (from 6-month-old to 1-year-old). However, seizures attacked again at 1Â year old and the frequency was as high as 1â2 times per day. By that time, CZP was added but with no effects. CBZ was added at 2Â years and 2Â months old, by which seizure frequency was markedly reduced, and the intermittent phase could be as long as 50Â days. EEG was at boundary condition at 2Â years of age. She presented with severe hypotonia and couldnât control head at age of 26Â months. After the seizure frequency was reduced, she showed significant developmental progress, that she could control head at 2Â years and 5Â months.</p>
          <p id="Par39">Patient 5 demonstrated milder phenotype. Epilepsy onset was at 5Â months old, with focal seizures followed by secondary generalization. EEG at age of 8Â months showed sharp and spike waves in the right frontal during sleeping period, and 3â4Â Hz slow-wave complexes in the occipital region during awake period. Seizures attacked 1â2 times per day. VPA and LEV were not effective at age of 8Â months. Then OXC was added at that time, no seizure was reported from then on. Developmental milestones were normal before the onset of seizures, with head control at 2Â months of age. After seizures onset, her development was slightly delayed that she could not sit independently until 9Â months. Patient 5 didnât show obvious cognition impairment.</p>
          <p id="Par40">Patient 6 had focal seizures starting at 6Â months old. Seizures attacked once every month. At 11Â months old, he was treated with LEV, but seizures still occurred occasionally. OXC was used at 18Â months of age, and since then no seizures were observed. Then two months later LEV was stopped. He presented with normal development and cognition.</p>
          <p id="Par41">The detailed clinical information of the six sporadic cases was summarized in TableÂ <xref rid="Tab4" ref-type="table">4</xref> and Additional file <xref rid="MOESM1" ref-type="media">1</xref>.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Clinical features of six sporadic cases with <italic>SCN8A</italic> gene mutation</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Patient</th><th>Sex</th><th>Age</th><th>Age of onset</th><th>Seizure type</th><th>Motor development</th><th>Cognitive outcome</th><th>EEG (age)</th><th>MRI</th><th>Respond to AED</th><th>Hypotonia</th></tr></thead><tbody><tr><td>Patient 1</td><td>M</td><td>1 y, 15Â m</td><td>2Â m</td><td>Focal seizure</td><td>Head control (15Â m), unable to sit alone (1 y, 15Â m)</td><td>Severe ID</td><td>Asynchronous bilateral spike, spike and wave discharges, with central, parietal and frontal predominance (3Â m)</td><td>None</td><td>OXC 30Â mg/kg/d, VPA 32Â mg/kg/d, CZP 0.6Â mg/d; no seizure from 1 y</td><td>
<bold>+</bold>
</td></tr><tr><td>Patient 2</td><td>M</td><td>2 y, 8Â m</td><td>3Â m</td><td>Focal seizure (3Â m), myoclonic seizure (9Â m)</td><td>Head control (2 y, 4Â m)</td><td>Severe ID</td><td>Generalized high amplitude multi-spike and slow waves (9Â m)</td><td>Normal (3Â m); slight widened cerebellar sulci (8Â m)</td><td>VPA 42Â mg/kg/d, LTG 4.5Â mg/kg/d, seizure free from 2 y</td><td>
<bold>+</bold>
</td></tr><tr><td>Patient 3</td><td>M</td><td>3 y, 6Â m</td><td>3.5Â m</td><td>Focal seizure, secondary generalized seizure, status epilepticus</td><td>Canât control head at 1-year-old</td><td>Severe ID</td><td>Diffuse slow waves in the background, spike at right central area during sleep period (1 y)</td><td>Normal (3Â m)</td><td>LEV 29.4Â mg/kg, OXC 49.4Â mg/kg, TPM 5.9Â mg/kg, VPA 23.5Â mg/kg; Seizures were not controlled âduring follow-up visit (before 1 y)</td><td>
<bold>+</bold>
</td></tr><tr><td>Patient 4</td><td>F</td><td>2 y, 6Â m</td><td>4Â m</td><td>Focal seizure (4Â m), generalized seizure (2 y, 2Â m)</td><td>Head control at age of 2 y, 5Â m</td><td>Severe ID</td><td>Boundary condition (4Â m)</td><td>Normal (2 y)</td><td>Seizures frequency reduced by VPA 36Â mg/kg/d, TPM 6.8Â mg/kg/d, CZP 0.5Â mg/d, and CBZ 18Â mg/kg/d</td><td>
<bold>+</bold>
</td></tr><tr><td>Patient 5</td><td>F</td><td>1 y</td><td>5Â m</td><td>Focal seizure with generalization</td><td>Head control (2Â m), sit independently (9Â m), stand with assistance (1 y)</td><td>Normal</td><td>sharp and spike waves in the right frontal during sleep period, and 3â4Â Hz slow-wave complexes in the occipital during awake period (8Â m)</td><td>Normal (7Â m)</td><td>Seizures were controlled by LEV (48.9Â mg/kg/d), VPA (26.7Â mg/kg/d), OXC 20Â mg/kg/d; no seizures were reported since 8-month-old</td><td>
<bold>â</bold>
</td></tr><tr><td>Patient 6</td><td>M</td><td>1 y, 8Â m</td><td>6Â m</td><td>Focal seizure</td><td>Head control (3Â m), sit alone (6Â m), walk (1 y, 4Â m)</td><td>Normal</td><td>Normal EEG (6Â m); Boundary condition (1 y, 6Â m)</td><td>Normal (1 y, 6Â m)</td><td>Controlled by OXC (30Â mg/kg/d), no seizures reported since 18Â m</td><td>
<bold>â</bold>
</td></tr></tbody></table><table-wrap-foot><p>
<italic>m</italic> months, <italic>y</italic> years, <italic>F</italic> female, <italic>M</italic> male, <italic>ID</italic> intellectual disability</p></table-wrap-foot></table-wrap>
</p>
        </sec>
      </sec>
    </sec>
    <sec id="Sec12">
      <title>Discussion</title>
      <p id="Par42">A total of seven <italic>SCN8A</italic> mutations were identified, of which three were <italic>novel</italic>. These new patients provide support for delineating the clinical features of patients with <italic>SCN8A</italic> mutations.</p>
      <p id="Par43">
<italic>SCN8A</italic> mutations have already been proved responsible for EIEE 13. Generally, patients had seizure onset within 6Â months after birth [<xref ref-type="bibr" rid="CR9">9</xref>]. The seizure semiology was variable, including focal seizures, clonic seizures, tonic-clonic seizures, epileptic spasms, myoclonic and absence seizures, etc. [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. The majority of affected patients had mild to severe psychomotor retardation. Hypotonia, hypertonia and dystonia were common as well [<xref ref-type="bibr" rid="CR9">9</xref>]. Patients with <italic>SCN8A</italic> mutations also have a high incidence of SUDEP [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. In our study, the clinical profiles of four patients (Patient 1â4) were in accordance with the characteristic of EIEE13. Seizures began at a mean age of 3.5Â months and were intractable. Focal seizure was the primary seizure type. All of them suffered from severe developmental delay and intellectual disability (TableÂ <xref rid="Tab4" ref-type="table">4</xref>). Hypotonia was also obvious. The other two patients (patient 5, and 6) presented with milder phenotype, which confirmed that diseases caused by <italic>SCN8A</italic> mutations had a broad phenotypic-spectrum.</p>
      <p id="Par44">Four mutations (those of patient 2, 3, 4, and 5) had been described previously. The clinical features of patient 2, 3, and 4 were quite similar as the characterization of patients with each same mutation previously described [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. The phenotype of patient 5 was much milder. With multi-drugs (LEV, VPA, OXC), no seizures were observed since 8Â months old. In addition, she didnât present obvious cognition impairment, whereas her phenotype was slightly more serious than the patients with the same mutation (c.5630AÂ &gt;Â G, p. Asn1877Ser) in Anandâs report [<xref ref-type="bibr" rid="CR16">16</xref>]. Anand et al. reported a family with <italic>SCN8A</italic> mutation, in which the proband and his father had early onset focal epileptic seizures without cognitive or neurological impairment. The seizures were controlled well by mono-therapy, with CZB and PHT, respectively. Additionally, in the report of Parrini et al., patients with the same mutation (c.5630AÂ &gt;Â G, p. Asn1877Ser) presented with drug resistant focal epilepsy and mild intellectual disability [<xref ref-type="bibr" rid="CR15">15</xref>]. Nevertheless, this mutation has also been reported to cause more severe phenotype including intractable epilepsy, developmental delay and intellectual disability [<xref ref-type="bibr" rid="CR16">16</xref>]. This study and previous reports suggest that same mutation in <italic>SCN8A</italic> can lead to a different phenotype.</p>
      <p id="Par45">Patient 6, with mutation (c.2671GÂ &gt;Â A, p.Val891Met) in <italic>SCN8A</italic>, had a benign clinical course. He presented no psychomotor retardation, and epilepsy was well controlled by mono-therapy. It was the first reported de novo <italic>SCN8A</italic> mutation relating with benign phenotype. Combined with previous reports, our study provided further evidence that <italic>SCN8A</italic> mutations could lead to a wild range of phenotypes.</p>
      <p id="Par46">To date, more than 100 <italic>SCN8A</italic> mutations have been reported, an overwhelming majority of which were de novo [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>â<xref ref-type="bibr" rid="CR29">29</xref>]. Only few inherited <italic>SCN8A</italic> mutations were reported. Trudeau et al. first reported a frame-shift mutation (c.5156_5157delCT, p.Pro1719fs) of <italic>SCN8A</italic> in a family with mental retardation and ataxia, but without epilepsy [<xref ref-type="bibr" rid="CR11">11</xref>]. Gardella et al. discovered a <italic>SCN8A</italic> mutation (c.4447GÂ &gt;Â A, p.Glu1483Lys) in 16 affected members of three families with BFIS/ICCA [<xref ref-type="bibr" rid="CR10">10</xref>]. Anand et al. identified a heterozygous mutation (c.5630AÂ &gt;Â G, p.Asn1877Ser) of <italic>SCN8A</italic> in a family with early onset epilepsy with no cognitive impairment [<xref ref-type="bibr" rid="CR16">16</xref>]. The heterozygous mutation (c.4793Â TÂ &gt;Â C, p.Val1598Ala) identified in our Chinese family was the forth reported inherited <italic>SCN8A</italic> mutation. In addition, all patients in this family were female, and <italic>PCDH19</italic> gene mutation was ruled out. The onset age ranged from 6Â months to preschool period. Two (I-2 and II-2) of them initialized as febrile convulsion, which evolved into afebrile seizures. The others initialized as focal seizures. Good seizure control was achieved in four of them with mono-therapy, and II-4 was seizure free even without treatment. While seizures were refractory inII-3. At the age of 17Â years, she died from SUDEP. Except II-3, the other five affected members had normal cognition and developmental profile. To the best of our knowledge, this is the only family among which different phenotypes presented in the members with the same <italic>SCN8A</italic> mutation. It is proposed that other genetic or non-genetic factors account for the different phenotypes. Unfortunately, as II-3 had passed away, the difference of genetic background between the affected members, which might explain their significant variation on phenotypes, was not available.</p>
      <p id="Par47">The reported mutations are scattered throughout the whole <italic>SCN8A</italic> channel [<xref ref-type="bibr" rid="CR9">9</xref>]. Among these mutations, Arg<sup>1872</sup> and Arg<sup>1617</sup> might be two mutational hotspots, which had been identified in more than ten independent patients [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. In vitro functional analysis proved that both of the mutations Arg<sup>1872</sup> and Arg<sup>1617</sup> impaired the Na<sub>v</sub>1.6 channel transition from open state to inactivated state, resulting in channel hyperactivity [<xref ref-type="bibr" rid="CR30">30</xref>]. Like Arg<sup>1617</sup>, the mutations c.2549GÂ &gt;Â A, p.Arg850Glu and c.694Â TÂ &gt;Â C, p.Ser232Pro identified in this study were located in S4 transmembrane segments (FigureÂ <xref rid="Fig3" ref-type="fig">3</xref>), which served as the voltage sensors for Na<sub>v</sub>1.6 activation. So, these two mutations might have the similar pathogenic mechanism as mutations at Arg<sup>1617</sup>. They might lead to elevating Na<sub>v</sub>1.6 channel activity by impairing channel inactivation.</p>
      <p id="Par48">Sodium channel blockers may be the rational candidate drugs for the treatment of epilepsy caused by <italic>SCN8A</italic> mutations, including OXC,CBZ, LTG, Phenobarbital (PB), TPM and PHT, etc. [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. For benign familial infantile epilepsy caused by <italic>SCN8A</italic> mutation, seizures were easily controlled by mono-therapy. While for the epileptic encephalopathy, seizures were not easy to control. Approximately half of patients showed good responses to sodium channel blockers, either as a reduction in seizures frequency or even seizure-free [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Up to 1/3 of patients were seizure-free after treatment with antiepileptic drugs [<xref ref-type="bibr" rid="CR9">9</xref>]. In our study, four sporadic patients were seizure-free by treatment with mono- or multi- antiepileptic drugs. All of them were treated with sodium channel blockers.</p>
    </sec>
    <sec id="Sec13">
      <title>Conclusions</title>
      <p id="Par49">
<italic>SCN8A</italic> mutation is not only associated with epileptic encephalopathy, but also can be the pathogenic cause of some benign phenotypes, such as BFIS/ICCA, especially the inherited mutations. Three <italic>novel SCN8A</italic> mutations were identified in this study. The huge difference among the family affected members, and the varied phenotype between patient 5 and patients previously reported with same mutation (c.5630AÂ &gt;Â G, p.Asn1877Ser), suggested that the same mutation in <italic>SCN8A</italic> can lead to quite different phenotypes. It is necessary to analyze <italic>SCN8A</italic> mutations in patients with early onset epilepsy with or without developmental delay or intellectual disability. The limited clinical evidence suggests that sodium channel blockers may be the good choice for patients with <italic>SCN8A</italic> mutations.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Additional files</title>
      <sec id="Sec14">
        <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12881_2017_460_MOESM1_ESM.docx"><label>Additional file 1:</label><caption><p>The record of seizures attack of patients with <italic>SCN8A</italic> mutations. This file included the seizure frequency of patients with <italic>SCN8A</italic> mutations, at different periods. (DOCX 16Â kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12881_2017_460_MOESM2_ESM.pdf"><label>Additional file 2:</label><caption><p>485 genes in the targeted-next generation sequencing panel. (PDF 45Â kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="12881_2017_460_MOESM3_ESM.docx"><label>Additional file 3:</label><caption><p>23 candidate genes identified in the Chinese family with epilepsy, by whole-exome sequencing. (DOCX 16Â kb)</p></caption></media></supplementary-material>
</p>
      </sec>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>AEDs</term>
          <def>
            <p id="Par5">Antiepileptic drugs</p>
          </def>
        </def-item>
        <def-item>
          <term>AIS</term>
          <def>
            <p id="Par6">Axonal initial segment</p>
          </def>
        </def-item>
        <def-item>
          <term>BFIS</term>
          <def>
            <p id="Par7">Benign infantile seizures</p>
          </def>
        </def-item>
        <def-item>
          <term>CBZ</term>
          <def>
            <p id="Par8">Carbamazepine</p>
          </def>
        </def-item>
        <def-item>
          <term>CZP</term>
          <def>
            <p id="Par9">Clonazepam</p>
          </def>
        </def-item>
        <def-item>
          <term>EEG</term>
          <def>
            <p id="Par10">Electroencephalography</p>
          </def>
        </def-item>
        <def-item>
          <term>EIEE</term>
          <def>
            <p id="Par11">Early infantile epileptic encephalopathy</p>
          </def>
        </def-item>
        <def-item>
          <term>ICCA</term>
          <def>
            <p id="Par12">Infantile convulsion and paroxysmal choreoathetosis</p>
          </def>
        </def-item>
        <def-item>
          <term>LEV</term>
          <def>
            <p id="Par13">Levetiracetam</p>
          </def>
        </def-item>
        <def-item>
          <term>LTG</term>
          <def>
            <p id="Par14">Lamotrigine</p>
          </def>
        </def-item>
        <def-item>
          <term>OXC</term>
          <def>
            <p id="Par15">Oxcarbazepine</p>
          </def>
        </def-item>
        <def-item>
          <term>PB</term>
          <def>
            <p id="Par16">Phenobarbital</p>
          </def>
        </def-item>
        <def-item>
          <term>PHT</term>
          <def>
            <p id="Par17">Phenytoin</p>
          </def>
        </def-item>
        <def-item>
          <term>SUDEP</term>
          <def>
            <p id="Par18">Sudden unexpected death in epilepsy</p>
          </def>
        </def-item>
        <def-item>
          <term>TPM</term>
          <def>
            <p id="Par19">Topiramate</p>
          </def>
        </def-item>
        <def-item>
          <term>VGSCs</term>
          <def>
            <p id="Par20">Voltage-gated sodium channels</p>
          </def>
        </def-item>
        <def-item>
          <term>VPA</term>
          <def>
            <p id="Par21">Valproic acid</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Electronic supplementary material</bold>
        </p>
        <p>The online version of this article (10.1186/s12881-017-0460-1) contains supplementary material, which is available to authorized users.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>We would like to thank the patients and their family for their cooperation in this study.</p>
      <sec id="FPar1">
        <title>Funding</title>
        <p id="Par50">The study was funded by 985 Peking University and Clinical Hospital Cooperation Project (2013-1-06), and Technology innovation talents special fund of Harbin Science and Technology Bureau (2016RAXYJ089).</p>
      </sec>
      <sec id="FPar2">
        <title>Availability of data and materials</title>
        <p id="Par51">The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</p>
      </sec>
    </ack>
    <notes notes-type="author-contribution">
      <title>Authorsâ contributions</title>
      <p>XHB, LPW, XRW, and SJY obtained the funding and design the research. QPZ, JRL and YC acquired and provided clinical data and samples from patient. HG performed the Whole-exome sequencing, Targeted NGS, PCR-Sanger sequencing and part of data analysis. JPW analyzed most of the data and draft the manuscript. XHB revised the manuscript. English language polishing was done by HG. All authors have read and approved the manuscript, and there are no conflicts of the manuscript.</p>
    </notes>
    <notes notes-type="COI-statement">
      <sec id="FPar3">
        <title>Ethics approval and consent to participate</title>
        <p id="Par52">The study was approved by Clinical Research Ethics Committee, Peking University (NM: IRB00001052-11087). Written informed consent was obtained from all patients or their parents.</p>
      </sec>
      <sec id="FPar4">
        <title>Consent for publication</title>
        <p id="Par53">Consent for publication (including medical data, and images) was obtained from the parents of all patients in this study.</p>
      </sec>
      <sec id="FPar5">
        <title>Competing interests</title>
        <p id="Par54">The authors declare that they have no competing interests.</p>
      </sec>
      <sec id="FPar6">
        <title>Publisherâs Note</title>
        <p id="Par55">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Catterall</surname>
              <given-names>WA</given-names>
            </name>
          </person-group>
          <article-title>From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels</article-title>
          <source>Neuron</source>
          <year>2000</year>
          <volume>26</volume>
          <issue>1</issue>
          <fpage>13</fpage>
          <lpage>25</lpage>
          <pub-id pub-id-type="doi">10.1016/S0896-6273(00)81133-2</pub-id>
          <?supplied-pmid 10798388?>
          <pub-id pub-id-type="pmid">10798388</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scheffer</surname>
              <given-names>IE</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>YH</given-names>
            </name>
            <name>
              <surname>Jansen</surname>
              <given-names>FE</given-names>
            </name>
            <name>
              <surname>Dibbens</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Dravet syndrome or genetic (generalized) epilepsy with febrile seizures plus?</article-title>
          <source>Brain and Development</source>
          <year>2009</year>
          <volume>31</volume>
          <issue>5</issue>
          <fpage>394</fpage>
          <lpage>400</lpage>
          <pub-id pub-id-type="doi">10.1016/j.braindev.2009.01.001</pub-id>
          <?supplied-pmid 19203856?>
          <pub-id pub-id-type="pmid">19203856</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shi</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Yasumoto</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kurahashi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nakagawa</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Fukasawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Uchiya</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hirose</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Clinical spectrum of SCN2A mutations</article-title>
          <source>Brain and Development</source>
          <year>2012</year>
          <volume>34</volume>
          <issue>7</issue>
          <fpage>541</fpage>
          <lpage>545</lpage>
          <pub-id pub-id-type="doi">10.1016/j.braindev.2011.09.016</pub-id>
          <?supplied-pmid 22029951?>
          <pub-id pub-id-type="pmid">22029951</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nakamura</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Osaka</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yamashita</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nakagawa</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Haginoya</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tohyama</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Okuda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wada</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Shimakawa</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical spectrum of SCN2A mutations expanding to Ohtahara syndrome</article-title>
          <source>Neurology</source>
          <year>2013</year>
          <volume>81</volume>
          <issue>11</issue>
          <fpage>992</fpage>
          <lpage>998</lpage>
          <pub-id pub-id-type="doi">10.1212/WNL.0b013e3182a43e57</pub-id>
          <?supplied-pmid 23935176?>
          <pub-id pub-id-type="pmid">23935176</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vanoye</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Gurnett</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Holland</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>George</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Kearney</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Novel SCN3A variants associated with focal epilepsy in children</article-title>
          <source>Neurobiol Dis</source>
          <year>2014</year>
          <volume>62</volume>
          <fpage>313</fpage>
          <lpage>322</lpage>
          <pub-id pub-id-type="doi">10.1016/j.nbd.2013.10.015</pub-id>
          <?supplied-pmid 24157691?>
          <pub-id pub-id-type="pmid">24157691</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hu</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hou</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Shu</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Distinct contributions of Na(v)1.6 and Na(v)1.2 in action potential initiation and backpropagation</article-title>
          <source>Nat Neurosci</source>
          <year>2009</year>
          <volume>12</volume>
          <issue>8</issue>
          <fpage>996</fpage>
          <lpage>1002</lpage>
          <pub-id pub-id-type="doi">10.1038/nn.2359</pub-id>
          <?supplied-pmid 19633666?>
          <pub-id pub-id-type="pmid">19633666</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tzoumaka</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Tischler</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Sangameswaran</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Eglen</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Hunter</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Novakovic</surname>
              <given-names>SD</given-names>
            </name>
          </person-group>
          <article-title>Differential distribution of the tetrodotoxin-sensitive Rpn4/NaCh6/Scn8a sodium channel in the nervous system</article-title>
          <source>J Neurosci Res</source>
          <year>2000</year>
          <volume>60</volume>
          <issue>1</issue>
          <fpage>37</fpage>
          <lpage>44</lpage>
          <pub-id pub-id-type="doi">10.1002/(SICI)1097-4547(20000401)60:1&lt;37::AID-JNR4&gt;3.0.CO;2-W</pub-id>
          <?supplied-pmid 10723066?>
          <pub-id pub-id-type="pmid">10723066</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meisler</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Helman</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hammer</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Fureman</surname>
              <given-names>BE</given-names>
            </name>
            <name>
              <surname>Gaillard</surname>
              <given-names>WD</given-names>
            </name>
            <name>
              <surname>Goldin</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Hirose</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ishii</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kroner</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Lossin</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>SCN8A encephalopathy: Research progress and prospects</article-title>
          <source>Epilepsia</source>
          <year>2016</year>
          <volume>57</volume>
          <issue>7</issue>
          <fpage>1027</fpage>
          <lpage>1035</lpage>
          <pub-id pub-id-type="doi">10.1111/epi.13422</pub-id>
          <?supplied-pmid 27270488?>
          <pub-id pub-id-type="pmid">27270488</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wagnon</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Meisler</surname>
              <given-names>MH</given-names>
            </name>
          </person-group>
          <article-title>Recurrent and Non-Recurrent Mutations of SCN8A in Epileptic Encephalopathy</article-title>
          <source>Front Neurol</source>
          <year>2015</year>
          <volume>6</volume>
          <fpage>104</fpage>
          <pub-id pub-id-type="doi">10.3389/fneur.2015.00104</pub-id>
          <?supplied-pmid 26029160?>
          <pub-id pub-id-type="pmid">26029160</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gardella</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Moller</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Schubert</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lemke</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Larsen</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Eiberg</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nothnagel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Thiele</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Altmuller</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Benign infantile seizures and paroxysmal dyskinesia caused by an SCN8A mutation</article-title>
          <source>Ann Neurol</source>
          <year>2016</year>
          <volume>79</volume>
          <issue>3</issue>
          <fpage>428</fpage>
          <lpage>436</lpage>
          <pub-id pub-id-type="doi">10.1002/ana.24580</pub-id>
          <?supplied-pmid 26677014?>
          <pub-id pub-id-type="pmid">26677014</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trudeau</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Dalton</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Day</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Ranum</surname>
              <given-names>LP</given-names>
            </name>
            <name>
              <surname>Meisler</surname>
              <given-names>MH</given-names>
            </name>
          </person-group>
          <article-title>Heterozygosity for a protein truncation mutation of sodium channel SCN8A in a patient with cerebellar atrophy, ataxia, and mental retardation</article-title>
          <source>J Med Genet</source>
          <year>2006</year>
          <volume>43</volume>
          <issue>6</issue>
          <fpage>527</fpage>
          <lpage>530</lpage>
          <pub-id pub-id-type="doi">10.1136/jmg.2005.035667</pub-id>
          <?supplied-pmid 16236810?>
          <pub-id pub-id-type="pmid">16236810</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Larsen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Carvill</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Gardella</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kluger</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schmiedel</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Barisic</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Depienne</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Brilstra</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Mang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nielsen</surname>
              <given-names>JE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The phenotypic spectrum of SCN8A encephalopathy</article-title>
          <source>Neurology</source>
          <year>2015</year>
          <volume>84</volume>
          <issue>5</issue>
          <fpage>480</fpage>
          <lpage>489</lpage>
          <pub-id pub-id-type="doi">10.1212/WNL.0000000000001211</pub-id>
          <?supplied-pmid 25568300?>
          <pub-id pub-id-type="pmid">25568300</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Veeramah</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>O'Brien</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Meisler</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Dib-Hajj</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Waxman</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Talwar</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Girirajan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Eichler</surname>
              <given-names>EE</given-names>
            </name>
            <name>
              <surname>Restifo</surname>
              <given-names>LL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>De novo pathogenic SCN8A mutation identified by whole-genome sequencing of a family quartet affected by infantile epileptic encephalopathy and SUDEP</article-title>
          <source>Am J Hum Genet</source>
          <year>2012</year>
          <volume>90</volume>
          <issue>3</issue>
          <fpage>502</fpage>
          <lpage>510</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ajhg.2012.01.006</pub-id>
          <?supplied-pmid 22365152?>
          <pub-id pub-id-type="pmid">22365152</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kong</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>SCN8A mutations in Chinese children with early onset epilepsy and intellectual disability</article-title>
          <source>Epilepsia</source>
          <year>2015</year>
          <volume>56</volume>
          <issue>3</issue>
          <fpage>431</fpage>
          <lpage>438</lpage>
          <pub-id pub-id-type="doi">10.1111/epi.12925</pub-id>
          <?supplied-pmid 25785782?>
          <pub-id pub-id-type="pmid">25785782</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parrini</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Marini</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mei</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Galuppi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cellini</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Pucatti</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Chiti</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Rutigliano</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bianchini</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Virdo</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Diagnostic Targeted Resequencing in 349 Patients with Drug-Resistant Pediatric Epilepsies Identifies Causative Mutations in 30 Different Genes</article-title>
          <source>Hum Mutat</source>
          <year>2017</year>
          <volume>38</volume>
          <issue>2</issue>
          <fpage>216</fpage>
          <lpage>225</lpage>
          <pub-id pub-id-type="doi">10.1002/humu.23149</pub-id>
          <?supplied-pmid 27864847?>
          <pub-id pub-id-type="pmid">27864847</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Anand</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Collett-White</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Orsini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jayapal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Trump</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Zaiwalla</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Jayawant</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Autosomal dominant SCN8A mutation with an unusually mild phenotype</article-title>
          <source>Eur J Paediatr Neurol</source>
          <year>2016</year>
          <volume>20</volume>
          <issue>5</issue>
          <fpage>761</fpage>
          <lpage>765</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejpn.2016.04.015</pub-id>
          <?supplied-pmid 27210545?>
          <pub-id pub-id-type="pmid">27210545</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takahashi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Okayama</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Araki</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Saitsu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Azuma</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Electroclinical features of epileptic encephalopathy caused by SCN8A mutation</article-title>
          <source>Pediatr Int</source>
          <year>2015</year>
          <volume>57</volume>
          <issue>4</issue>
          <fpage>758</fpage>
          <lpage>762</lpage>
          <pub-id pub-id-type="doi">10.1111/ped.12622</pub-id>
          <?supplied-pmid 25951352?>
          <pub-id pub-id-type="pmid">25951352</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Estacion</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>O'Brien</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Conravey</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hammer</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Waxman</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Dib-Hajj</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Meisler</surname>
              <given-names>MH</given-names>
            </name>
          </person-group>
          <article-title>A novel de novo mutation of SCN8A (Nav1.6) with enhanced channel activation in a child with epileptic encephalopathy</article-title>
          <source>Neurobiol Dis</source>
          <year>2014</year>
          <volume>69</volume>
          <fpage>117</fpage>
          <lpage>123</lpage>
          <pub-id pub-id-type="doi">10.1016/j.nbd.2014.05.017</pub-id>
          <?supplied-pmid 24874546?>
          <pub-id pub-id-type="pmid">24874546</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Kovel</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Meisler</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Brilstra</surname>
              <given-names>EH</given-names>
            </name>
            <name>
              <surname>van Berkestijn</surname>
              <given-names>FM</given-names>
            </name>
          </person-group>
          <article-title>van T SR, van Lieshout S, Nijman IJ, O'Brien JE, Hammer MF, Estacion M <italic>e</italic>t al.: Characterization of a de novo SCN8A mutation in a patient with epileptic encephalopathy</article-title>
          <source>Epilepsy Res</source>
          <year>2014</year>
          <volume>108</volume>
          <issue>9</issue>
          <fpage>1511</fpage>
          <lpage>1518</lpage>
          <pub-id pub-id-type="doi">10.1016/j.eplepsyres.2014.08.020</pub-id>
          <?supplied-pmid 25239001?>
          <pub-id pub-id-type="pmid">25239001</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blanchard</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Willemsen</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Walker</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Dib-Hajj</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Waxman</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Jongmans</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Kleefstra</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>van de Warrenburg</surname>
              <given-names>BP</given-names>
            </name>
            <name>
              <surname>Praamstra</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Nicolai</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>De novo gain-of-function and loss-of-function mutations of SCN8A in patients with intellectual disabilities and epilepsy</article-title>
          <source>J Med Genet</source>
          <year>2015</year>
          <volume>52</volume>
          <issue>5</issue>
          <fpage>330</fpage>
          <lpage>337</lpage>
          <pub-id pub-id-type="doi">10.1136/jmedgenet-2014-102813</pub-id>
          <?supplied-pmid 25725044?>
          <pub-id pub-id-type="pmid">25725044</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vaher</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Noukas</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nikopensius</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kals</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Annilo</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nelis</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ounap</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Reimand</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Talvik</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Ilves</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>De novo SCN8A mutation identified by whole-exome sequencing in a boy with neonatal epileptic encephalopathy, multiple congenital anomalies, and movement disorders</article-title>
          <source>J Child Neurol</source>
          <year>2014</year>
          <volume>29</volume>
          <issue>12</issue>
          <fpage>P202</fpage>
          <lpage>P206</lpage>
          <pub-id pub-id-type="doi">10.1177/0883073813511300</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mercimek-Mahmutoglu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cordeiro</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hewson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Callen</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Donner</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Hahn</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Kannu</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Minassian</surname>
              <given-names>BA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Diagnostic yield of genetic testing in epileptic encephalopathy in childhood</article-title>
          <source>Epilepsia</source>
          <year>2015</year>
          <volume>56</volume>
          <issue>5</issue>
          <fpage>707</fpage>
          <lpage>716</lpage>
          <pub-id pub-id-type="doi">10.1111/epi.12954</pub-id>
          <?supplied-pmid 25818041?>
          <pub-id pub-id-type="pmid">25818041</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ohba</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lerman-Sagie</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Lev</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Terashima</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kubota</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kawawaki</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Matsufuji</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kojima</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Early onset epileptic encephalopathy caused by de novo SCN8A mutations</article-title>
          <source>Epilepsia</source>
          <year>2014</year>
          <volume>55</volume>
          <issue>7</issue>
          <fpage>994</fpage>
          <lpage>1000</lpage>
          <pub-id pub-id-type="doi">10.1111/epi.12668</pub-id>
          <?supplied-pmid 24888894?>
          <pub-id pub-id-type="pmid">24888894</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Singh</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jayapal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Goyal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jungbluth</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Lascelles</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Early-onset movement disorder and epileptic encephalopathy due to de novo dominant SCN8A mutation</article-title>
          <source>Seizure</source>
          <year>2015</year>
          <volume>26</volume>
          <fpage>69</fpage>
          <lpage>71</lpage>
          <pub-id pub-id-type="doi">10.1016/j.seizure.2015.01.017</pub-id>
          <?supplied-pmid 25799905?>
          <pub-id pub-id-type="pmid">25799905</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carvill</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Heavin</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Yendle</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>McMahon</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>O'Roak</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Cook</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dorschner</surname>
              <given-names>MO</given-names>
            </name>
            <name>
              <surname>Weaver</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Calvert</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1</article-title>
          <source>Nat Genet</source>
          <year>2013</year>
          <volume>45</volume>
          <issue>7</issue>
          <fpage>825</fpage>
          <lpage>830</lpage>
          <pub-id pub-id-type="doi">10.1038/ng.2646</pub-id>
          <?supplied-pmid 23708187?>
          <pub-id pub-id-type="pmid">23708187</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dyment</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Tetreault</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Beaulieu</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Hartley</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Chardon</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Marcadier</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sawyer</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Mosca</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Innes</surname>
              <given-names>AM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Whole-exome sequencing broadens the phenotypic spectrum of rare pediatric epilepsy: a retrospective study</article-title>
          <source>Clin Genet</source>
          <year>2015</year>
          <volume>88</volume>
          <issue>1</issue>
          <fpage>34</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="doi">10.1111/cge.12464</pub-id>
          <?supplied-pmid 25046240?>
          <pub-id pub-id-type="pmid">25046240</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Allen</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Berkovic</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Cossette</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Delanty</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Dlugos</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Eichler</surname>
              <given-names>EE</given-names>
            </name>
            <name>
              <surname>Epstein</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Glauser</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Goldstein</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>De novo mutations in epileptic encephalopathies</article-title>
          <source>Nature</source>
          <year>2013</year>
          <volume>501</volume>
          <issue>7466</issue>
          <fpage>217</fpage>
          <lpage>221</lpage>
          <pub-id pub-id-type="doi">10.1038/nature12439</pub-id>
          <?supplied-pmid 23934111?>
          <pub-id pub-id-type="pmid">23934111</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <mixed-citation publication-type="other">Trump N, McTague A, Brittain H, Papandreou A, Meyer E, Ngoh A, Palmer R, Morrogh D, Boustred C, Hurst JA, et al. Improving diagnosis and broadening the phenotypes in early-onset seizure and severe developmental delay disorders through gene panel analysis. J Med Genet. 2016;</mixed-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>O'Brien</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Meisler</surname>
              <given-names>MH</given-names>
            </name>
          </person-group>
          <article-title>Sodium channel SCN8A (Nav1.6): properties and de novo mutations in epileptic encephalopathy and intellectual disability</article-title>
          <source>Front Genet</source>
          <year>2013</year>
          <volume>4</volume>
          <fpage>213</fpage>
          <pub-id pub-id-type="doi">10.3389/fgene.2013.00213</pub-id>
          <?supplied-pmid 24194747?>
          <pub-id pub-id-type="pmid">24194747</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wagnon</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Barker</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Hounshell</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Haaxma</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Shealy</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Moss</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Parikh</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Messer</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Meisler</surname>
              <given-names>MH</given-names>
            </name>
          </person-group>
          <article-title>Pathogenic mechanism of recurrent mutations of SCN8A in epileptic encephalopathy</article-title>
          <source>Ann Clin Transl Neurol</source>
          <year>2016</year>
          <volume>3</volume>
          <issue>2</issue>
          <fpage>114</fpage>
          <lpage>123</lpage>
          <pub-id pub-id-type="doi">10.1002/acn3.276</pub-id>
          <?supplied-pmid 26900580?>
          <pub-id pub-id-type="pmid">26900580</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moller</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Johannesen</surname>
              <given-names>KM</given-names>
            </name>
          </person-group>
          <article-title>Precision Medicine: SCN8A Encephalopathy Treated with Sodium Channel Blockers</article-title>
          <source>Neurotherapeutics</source>
          <year>2016</year>
          <volume>13</volume>
          <issue>1</issue>
          <fpage>190</fpage>
          <lpage>191</lpage>
          <pub-id pub-id-type="doi">10.1007/s13311-015-0403-5</pub-id>
          <?supplied-pmid 26553437?>
          <pub-id pub-id-type="pmid">26553437</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boerma</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Braun</surname>
              <given-names>KP</given-names>
            </name>
            <name>
              <surname>van den Broek</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>van Berkestijn</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Swinkels</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Hagebeuk</surname>
              <given-names>EO</given-names>
            </name>
            <name>
              <surname>Lindhout</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>van Kempen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Boon</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nicolai</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Remarkable Phenytoin Sensitivity in 4 Children with SCN8A-related Epilepsy: A Molecular Neuropharmacological Approach</article-title>
          <source>Neurotherapeutics</source>
          <year>2016</year>
          <volume>13</volume>
          <issue>1</issue>
          <fpage>192</fpage>
          <lpage>197</lpage>
          <pub-id pub-id-type="doi">10.1007/s13311-015-0372-8</pub-id>
          <?supplied-pmid 26252990?>
          <pub-id pub-id-type="pmid">26252990</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>